RG
COGT icon

Redmile Group’s Cogent Biosciences COGT Stock Holding History

Redmile Group’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.5M Sell
503,321
-184,715
-27% -$6.46M 1.31% 16
2026
Q1 		$26.5M Sell
688,036
-749,882
-52% -$27.7M 1.75% 12
2025
Q4 		$51.1M Sell
1,437,918
-771,200
-35% -$21.7M 3.76% 8
2025
Q3 		$31.7M Buy
2,209,118
+761,078
+53% +$9.02M 3.09% 12
2025
Q2 		$10.4M Sell
1,448,040
-1,767,986
-55% -$9.8M 1.11% 21
2025
Q1 		$19.3M Sell
3,216,026
-338,810
-10% -$2.66M 1.82% 18
2024
Q4 		$27.7M Sell
3,554,836
-929,544
-21% -$9.26M 1.93% 20
2024
Q3 		$48.4M Sell
4,484,380
-315,593
-7% -$3.07M 2.85% 13
2024
Q2 		$40.5M Buy
4,799,973
+837,371
+21% +$6.35M 2.45% 14
2024
Q1 		$26.6M Buy
3,962,602
+1,048,580
+36% +$6.48M 0.98% 36
2023
Q4 		$17.1M Buy
2,914,022
+860,689
+42% +$6.6M 0.61% 43
2023
Q3 		$20M Hold
2,053,333
– – 0.95% 32
2023
Q2 		$24.3M Buy
+2,053,333
New +$23.6M 0.93% 32

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Redmile Group's COGT Position: Q2 2026 in Review

Redmile Group reduced its Cogent Biosciences (COGT) stake by 27% in Q2 2026, selling an estimated $6.46M and leaving 503,321 shares worth $19.5M. The position accounts for 1.31% of the portfolio, ranked #16.

Redmile Group first reported a position in COGT in Q2 2023 and has held it in 13 quarters since. The position peaked at $51.1M in Q4 2025. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Redmile Group held 503,321 shares of Cogent Biosciences worth $19.5M as of Q2 2026.
  • Redmile Group sold 184,715 Cogent Biosciences shares in Q2 2026, an estimated $6.46M.
  • Cogent Biosciences made up 1.31% of Redmile Group's portfolio in Q2 2026, its #16 holding.
  • Redmile Group first reported a position in Cogent Biosciences in Q2 2023 and has held it in 13 quarters since.
  • Redmile Group's Cogent Biosciences position peaked at $51.1M in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.